美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ZURA BIO LIMITED C/WTS 20/03/2028 (TO PUR ORD)

1.08

0.0000

成交量：- -

成交額：- -

市值：1,863.00萬

市盈率：4.67

高：1.08

開：1.08

低：1.08

收：1.08

52周最高：1.08

52周最低：1.08

股本：1,725.00萬

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.2314

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

ZURA BIO LIMITED C/WTS 20/03/2028 (TO PUR ORD)

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.zurabio.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Zura Bio Limited成立於2022年1月。該公司是一家臨床階段的生物技術公司，正在推進兩項主要資產，包括用於治療斑禿和其他炎症性疾病的ZB-168，以及用於治療慢性阻塞性肺病（COPD）和哮喘的torudokimab。Zura的目標是開發ZB-168的治療適應症組合，並專註於證明其療效、安全性、給藥便利性和作用機制，最初用於斑禿。Torudokimab是一種全人源、高親和力單克隆抗體，可中和IL33，目前處於2期臨床開發階段。IL33在COPD和哮喘中都是經過驗證的藥物靶點。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ZURAW/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZURAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZURAW\",,,,,undefined,":{"symbol":"ZURAW","market":"US","secType":"STK","nameCN":"ZURA BIO LIMITED C/WTS 20/03/2028 (TO PUR ORD)","latestPrice":1.08,"timestamp":1774625281439,"preClose":1.08,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":17250000,"eps":0.23135,"marketStatus":"交易中","change":0,"latestTime":"03-27 11:28:01 EDT","open":1.08,"high":1.08,"low":1.08,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.23135,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.08,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZURAW\",,,,,undefined,":{"symbol":"ZURAW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":17250000,"dividePrice":0,"high":1.08,"amplitude":0,"preClose":1.08,"low":1.08,"week52Low":1.08,"pbRate":"--","week52High":1.08,"institutionHeld":0,"latestPrice":1.08,"eps":0.23135,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.23135,"open":1.08,"prevYearClose":1.08,"prevWeekClose":1.08,"prevMonthClose":1.08,"prevQuarterClose":1.08,"fiveDayClose":1.08,"twentyDayClose":1.08,"sixtyDayClose":1.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZURAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-28","symbol":"ZURAW","reason":null,"defaultRemindTime":1724851800000,"announcedDate":"2024-08-23","type":"delisting","dateTimestamp":1724817600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZURAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZURAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.zurabio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Zura Bio Limited成立於2022年1月。該公司是一家臨床階段的生物技術公司，正在推進兩項主要資產，包括用於治療斑禿和其他炎症性疾病的ZB-168，以及用於治療慢性阻塞性肺病（COPD）和哮喘的torudokimab。Zura的目標是開發ZB-168的治療適應症組合，並專註於證明其療效、安全性、給藥便利性和作用機制，最初用於斑禿。Torudokimab是一種全人源、高親和力單克隆抗體，可中和IL33，目前處於2期臨床開發階段。IL33在COPD和哮喘中都是經過驗證的藥物靶點。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.294329},{"month":2,"riseRate":0.4,"avgChangeRate":0.046993},{"month":3,"riseRate":0.2,"avgChangeRate":-0.010638},{"month":4,"riseRate":0.5,"avgChangeRate":0.138327},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003738},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082813},{"month":7,"riseRate":0.75,"avgChangeRate":0.606548},{"month":8,"riseRate":0.25,"avgChangeRate":-0.075625},{"month":9,"riseRate":0,"avgChangeRate":-0.068445},{"month":10,"riseRate":0.2,"avgChangeRate":-0.016891},{"month":11,"riseRate":0.4,"avgChangeRate":0.066661},{"month":12,"riseRate":0.2,"avgChangeRate":-0.068402}],"exchange":"NASDAQ","name":"ZURA BIO LIMITED C/WTS 20/03/2028 (TO PUR ORD)","nameEN":"ZURA BIO LIMITED C/WTS 20/03/2028 (TO PUR ORD)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ZURAW\",market:\"US\",,,undefined,":null}}